Bladder Sparing Treatment of Tislelizumab, Gemcitabine and Cisplatin for Patients With PD-L1 Positive Muscle Invasive Bladder Cancer

NCT05401279 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Urothelial Carcinoma Bladder
PD-1 Inhibitor

Interventions

DRUG: Tislelizumab
DRUG: Gemcitabine
DRUG: Cisplatin

Sponsor

RenJi Hospital